(-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 713-725

  He, Li ^a   Zhang, Erying ^a   Shi, Jingli ^a   Li, Xiangyong ^a   Zhou, Keyuan ^a   Zhang, Qunzhou ^a,b   Le, Anh D ^b   Tang, Xudong ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

( ) Epigallocatechin 3 gallate (EGCG); Angiogenesis; HIF 1 ; Human papillomavirus (HPV); Non small cell lung cancer (NSCLC)

Indexed keywords

CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN E6; PROTEIN E7; PROTEIN KINASE B; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CATECHIN; DRUG DERIVATIVE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HIF1A PROTEIN, HUMAN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STIMULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; GENE EXPRESSION; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CATECHIN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS 16; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERLEUKIN-8; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 84875848697     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2063-z     Document Type: Article

References (43)

1. Deleuran T, Søgaard M, Frøslev T, Rasmussen TR, Jensen HK, Friis S, Olsen M (2012) Completeness of TNM staging of small-cell and non-small-cell lung cancer in the Danish cancer registry, 2004-2009. Clin Epidemiol 4:39-44
2. Zhang Y, Gu C, Shi H, Zhang A, Kong X, Bao W, Deng D, Ren L, Gu D (2012) Association between C3orf21, TP63 polymorphisms and environment and NSCLC in never-smoking Chinese population. Gene 497:93-97
3. Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y (2011) Non-small cell lung cancer in never smokers as a representative non-smoking-associated lung cancer': epidemiology and clinical features. Int J Clin Oncol 16:287-293
4. Ciotti M, Giuliani L, Ambrogi V, Ronci C, Benedetto A, Mineo TC, Syrjänen K, Favalli C (2006) Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer. Oncol Rep 16:183-189
5. Srinivasan M, Taioli E, Ragin CC (2009) Human papillomavirus type 16 and 18 in primary lung cancers - a meta-analysis. Carcinogenesis 30:1722-1728
6. Baba M, Castillo A, Koriyama C, Yanagi M, Matsumoto H, Natsugoe S, Shuyama KY, Khan N, Higashi M, Itoh T, Eizuru Y, Aikou T, Akiba S (2010) Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas. Oncol Rep 23:1085-1092
7. Aguayo F, Anwar M, Koriyama C, Castillo A, Sun Q, Morewaya J, Eizuru Y, Akiba S (2010) Human papillomavirus-16 presence and physical status in lung carcinomas from Asia. Infect Agent Cancer 5:20-26
8. Zhang J, Wang T, Han M, Yang ZH, Liu LX, Chen Y, Zhang L, Hu HZ, Xi MR (2010) Variation of Human papillomavirus 16 in cervical and lung cancers in Sichuan, China. Acta Virol 54:247-253
9. Krikelis D, Tzimagiorgis G, Georgiou E, Destouni C, Agorastos T, Haitoglou C, Kouidou S (2010) Frequent presence of incomplete HPV16 E7 ORFs in lung carcinomas: memories of viral infection. J Clin Virol 49:169-174
10. Joh J, Jenson AB, Moore GD, Rezazedeh A, Slone SP, Ghim SJ, Kloecker GH (2010) Human papillomavirus (HPV) and Merkel cell polyomavirus (MCPyV) in non small cell lung cancer. Exp Mol Pathol 89:222-226
11. Li G, He L, Zhang E, Shi J, Zhang Q, Le AD, Zhou K, Tang X (2011) Overexpression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1 alpha and VEGF expression in non-small cell lung cancer cells. Cancer Lett 311:160-170
12. Yohena T, Yoshino I, Takenaka T, Kameyama T, Ohba T, Kuniyoshi Y, Maehara Y (2009) Upregulation of hypoxia-inducible factor-1alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol l4:284-290
13. Zuo S, Ji Y, Wang J, Guo J (2008) Expression and clinical implication of HIF-1alpha and VEGF-C in non-small cell lung cancer. J Huazhong Univ Sci Technol Med Sci 28:674-676
14. Kim WY, Oh SH, Woo JK, Hong WK, Lee HY (2009) Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1 alpha. Cancer Res 69:1624-1632
15. Liu Y, Bernauer AM, Yingling CM, Belinsky SA (2012) HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis 33:1187-1192
16. Kuo WH, Shih CM, Lin CW, Cheng WE, Chen SC, Chen W, Lee YL (2012) Association of hypoxia inducible factor-1α polymorphisms with susceptibility to non-small-cell lung cancer. Transl Res 159:42-50
17. Jackson AL, Zhou B, Kim WY (2010) HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets 14:1047-1057
18. Lambert JD, Yang CS (2003) Mechanisms of cancer prevention by tea constituents. J Nutr 133:3262S-3267S (Pubitemid 37222254)
19. Wang H, Bian S, Yang CS (2011) Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α. Carcinogenesis 32:1881-1889
20. Shim JH, Su ZY, Chae JI, Kim DJ, Zhu F, Ma WY, Bode AM, Yang CS, Dong Z (2010) Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev Res (Phila) 3:670-679
21. Yamauchi R, Sasaki K, Yoshida K (2009) Identification of epigallocatechin-3-gallate in green tea polyphenols as a potent inducer of p53-dependent apoptosis in the human lung cancer cell line A549. Toxicol In Vitro 23:834-839
22. Sadava D, Whitlock E, Kane SE (2007) The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun 360:233-237 (Pubitemid 46994711)
23. Deng YT, Lin JK (2011) EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest. Fertil Steril 96:1021-1028
24. Xu H, Becker CM, Lui WT, Chu CY, Davis TN, Kung AL, Birsner AE, D'Amato RJ, Wai Man GC, Wang CC (2011) Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. J Agric Food Chem 59:13318-13327
25. Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Kubota M, Adachi S, Tsurumi H, Hara Y, Moriwaki H (2010) (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem Biol Interact 185:247-252
26. Zhu BH, Chen HY, Zhan WH, Wang CY, Cai SR, Wang Z, Zhang CH, He YL (2011) (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. World J Gastroenterol 17:2315-2325
27. Tudoran O, Soritau O, Balacescu O, Balacescu L, Braicu C, Rus M, Gherman C, Virag P, Irimie F, Berindan-Neagoe I (2012) Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumour cells. J Cell Mol Med 16:520-530
28. Tang FY, Nguyen N, Meydani M (2003) Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Int J Cancer 106:871-878 (Pubitemid 37071665)
29. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD (2006) Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 5:1227-1238 (Pubitemid 43881315)
30. Thomas R, Kim MH (2005) Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem Biophys Res Commun 334:543-548 (Pubitemid 40982400)
31. Manalo DJ, Baek JH, Buehler PW, Struble E, Abraham B, Alayash AI (2011) Inactivation of prolyl hydroxylase domain (PHD) protein by epigallocatechin (EGCG) stabilizes hypoxia-inducible factor (HIF-1α) and induces hepcidin (Hamp) in rat kidney. Biochem Biophys Res Commun 416:421-426
32. Wang H, Bian S, Yang CS (2011) Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α. Carcinogenesis 32:1881-1889
33. Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, Le Bourhis X (2010) Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer 9:157-169
34. Menges CW, Baglia LA, Lapoint R, McCance DJ (2006) Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res 66:5555-5559 (Pubitemid 43927104)
35. Kim SH, Juhnn YS, Kang S, Park SW, Sung MW, Bang YJ, Song YS (2006) Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1, 2 and PI3K/Akt. Cell Mol Life Sci 63:930-938 (Pubitemid 43724080)
36. Das M, Wakelee H (2012) Targeting VEGF in lung cancer. Expert Opin Ther Targets 16:395-406
37. Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320:130-137
38. Hu Y, Liu J, Huang H (2012) Recent agents targeting HIF-1α for cancer therapy. J Cell Biochem. doi: 10.1002/jcb.24390. (Epub ahead of print)
39. Domingo DS, Camouse MM, Hsia AH, Matsui M, Maes D, Ward NL, Cooper KD, Baron ED (2010) Anti-angiogenic effects of epigallocatechin-3-gallate in human skin. Int J Clin Exp Pathol 3:705-709
40. Zhu Z, Wang Y, Liu Z, Wang F, Zhao Q (2012) Inhibitory effects of epigallocatechin-3-gallate on cell proliferation and the expression of HIF-1α and P-gp in the human pancreatic carcinoma cell line PANC-1. Oncol Rep 27:1567-1572
41. Shankar S, Marsh L, Srivastava RK (2013) EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Mol Cell Biochem 372:83-94
42. Syed DN, Afaq F, Kweon MH, Hadi N, Bhatia N, Spiegelman VS, Mukhtar H (2007) Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activation in normal human bronchial epithelial cells. Oncogene 26:673-682 (Pubitemid 46204247)
43. Tang X, Zhang Q, Nishitani J, Brown J, Shi S, Le AD (2007) Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 13:2568-2576 (Pubitemid 46795128)